欧洲联盟委员会核准FILSPARI,这是一种治疗肾病IgA肾病的新药物。 European Commission approves FILSPARI, a new drug for treating kidney condition IgA nephropathy.

欧洲联盟委员会批准了FILSPALI的标准批准,FILSPALI是一种治疗患有IgA肾病(肾病)的成年人的新药物。 The European Commission has granted standard approval for FILSPARI, a new drug for treating adults with primary IgA nephropathy, a kidney condition. 核准基于研究结果,表明FILSPALI与现有治疗相比,肾功能下降速度大大减缓。 Approval is based on study results showing FILSPARI significantly slows kidney function decline compared to existing treatments. 该药物可在德国、奥地利和瑞士获得,是欧洲批准的唯一非抑制性药物疗法。 The drug, available in Germany, Austria, and Switzerland, is the only non-immunosuppressive therapy of its kind approved in Europe.